Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



First production and administration of Axumin® (fluciclovine (18F)) in France

Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that the first commercial production of Axumin® (fluciclovine (18F)) in France occurred recently, with the first French patients being dosed.  Axumin is a novel molecular imaging agent approved in the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.

Read the rest of entry »

Arecor to attend the 37th Annual J.P. Morgan Healthcare Conference

Arecor Ltd, the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah Howell (Chief Executive Officer) and Dr Jan Jezek (Chief Scientific Officer) will be attending the 37th Annual J.P. Morgan Healthcare Conference, San Francisco, CA.  

Read the rest of entry »

Call for Cross-Cluster Proof of Concept proposals

The call is designed to stimulate collaboration across sectors and disciplines, and to allow industry to take full advantage of the EnergyTec, HealthTec, and Space Clusters at Harwell.

Read the rest of entry »

AMSBIO Expands Wnt Signaling Pathway Product Portfolio

AMSBIO has expanded its range of Wingless/Integrated (Wnt) recombinant proteins, stable reporter cell lines, antibodies and ELISA kits to assist researchers in the fields of developmental biology and oncology.
 

Read the rest of entry »

Genomics plc today announces second close of its Series B financing, raising a further £8 million, bringing the total round to £33 million

Genomics plc, the data science company specialising in the use of human genetic nformation to improve drug development, today announced that it has successfully completed a second close of its Series B financing round. The second close, which was oversubscribed, raised an additional £8 million, bringing the total raised in the round to £33 million.

Read the rest of entry »

AMSBIO introduces ALiCE® - a new high yield cell-free protein expression system.

Cell-free protein expression (CFPE) is today used by protein chemists to quickly produce small amounts of proteins when screening DNA libraries. However current technologies are limited and there is a need for higher protein expression yields.

Read the rest of entry »

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.

Read the rest of entry »

Birmingham to lead ground-breaking research into patient experience of cell therapies

Birmingham health researchers, with industry partners including health technology companies Dignio and Datatrial, have been awarded £1.1 million by UK Research & Innovation (UKRI)’s Innovate UK, to investigate patients’ experience of cell and gene therapies.

Read the rest of entry »

Chronos Therapeutics Announces Positive Pre-clinical Proof of Concept in MS Fatigue Model

Chronos Therapeutics Announces Positive Pre-clinical Proof of Concept in MS Fatigue Model. Patents for the Fatigue programme awarded in USA and Europe. 

Read the rest of entry »

PCI Clinical Services to Showcase Expertise in Phase I Clinical Trials in Australia

Philadelphia, USA – December 3, 2018 PCI Pharma Services (PCI), full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry, will showcase its expertise in Phase I Clinical Trials in Australia with a series of West Coast US seminars in January 2019. 

Read the rest of entry »

Pages: Previous1234567...45NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.